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Department, St. Jude Medical Italy, Milan, Italy.BACKGROUND Remote monitoring (RM) of cardiac implantable
electronic devices has been demonstrated to improve outpatient
clinic workﬂow and patient management. However, few data are
available on the socioeconomic impact of RM.
OBJECTIVE The aim of this study was to assess the costs and
beneﬁts of RM compared with standard care (SC).
METHODS We used 12-month patient data from the Health Economics
Evaluation Registry for Remote Follow-up (TARIFF) study (N¼ 209; RM:
n¼ 102 (48.81%); SC: n¼ 107 (51.19%)). Cost comparison was made
from 2 perspectives: the health care system (HCS) and patients. The use
of health care resources was deﬁned on the basis of hospital clinical
folders. Out-of-pocket expenses were reported directly by patients.
RESULTS HCS perspective: The overall mean annual cost per patient
in the SC group (€1044.89 ± €1990.47) was signiﬁcantly higher than
in the RM group (€482.87± €2488.10) (Po .0001), with a reduction
of 53.87% being achieved in the RM group. The primary driver of cost
reduction was the cost of cardiovascular hospitalizations (SC:
€`886.67 ± €1979.13 vs RM: €432.34 ± €2488.10; P ¼ .0030).Dr Ricci has received minor consultancy fees from Medtronic and Sorin
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1547-5271/$-see front matter B 2016 The Authors. Published by Elsevier Inc. on
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
All rights reserved.Patient and caregiver perspective: The annual cost incurred by patients
was signiﬁcantly higher in the SC group than in the RM group (SC:
€169.49 ± €189.50 vs RM: €56.87 ± €80.22; Po .0001). Patients’
quality-adjusted life-years were not signiﬁcantly different between
the groups. Provider perspective: The total number of inhospital
device follow-up visits was reduced by 58.78% in the RM group.
CONCLUSION RM of patients with cardiac implantable electronic
devices (CIEDs) is cost saving from the perspectives of the HCS,
patients, and caregivers. Introducing appropriate reimbursements
will make RM sustainable even for the provider, i.e. the hospitals
which provide the service and encourage widespread adoption of RM.
KEYWORDS Telemedicine; Remote monitoring; Implantable
cardioverter-deﬁbrillator; Reimbursement; Cost-effectiveness
(Heart Rhythm 2017;14:50–57) I 2016 The Authors. Published by
Elsevier Inc. on behalf of Heart Rhythm Society. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). All rights
reserved.Background
The remote monitoring (RM) of cardiac implantable elec-
tronic devices (CIEDs) has a record of improved clinicaloutcomes. Indeed, patients undergoing RM have been shown
to have lower mortality than those not on RM.1 Moreover,
the 3-year all-cause hospitalization rate has proved to be
signiﬁcantly lower in patients with RM. In spite of its clinical
beneﬁts, however, RM is not universally adopted.1–3 RM
offers a unique opportunity to improve clinic efﬁciency and
to provide continuous monitoring of device functioning
and patients’ clinical status, as established in the recently
published HRS consensus document.4 Several trials have
demonstrated the effectiveness of RM in the early detectionbehalf of Heart Rhythm Society. This is an open access article under the CC
http://dx.doi.org/10.1016/j.hrthm.2016.09.008
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promising patient safety.5–8 Finally, RM has been associated
with high patient acceptance and satisfaction and with
increased adherence to programmed follow-up.9
The cost-effectiveness of RM of CIEDs continues to be a
matter of debate, and there is a dearth of information on cost
analysis from the perspectives of the payer, that is, the
national health care system (HCS),10–13 of the providers, that
is, the hospitals which provide the service, and also of the
patients and caregivers.
The Health Economics Evaluation Registry for Remote
Follow-up (TARIFF) (clinicaltrials.gov ID: NCT01075516)
study was designed with the objectives of quantifying the
costs and beneﬁts of both RM and standard care (SC) from
the perspectives of 3 major stakeholders: the payer, the
provider, and the patient.
Methods
Data
We used data collected from the TARIFF patient cohort for
this cost-analysis. The TARIFF study design and data
collection method are described in detail elsewhere.14
Brieﬂy, the TARIFF study was a prospective, nonrandom-
ized, multicenter clinical trial designed to assess the eco-
nomic beneﬁts of RM follow-up in comparison with SC
follow-up. From December 2009 to March 2011, 209
patients in whom a St. Jude Medical (Sylmar, CA) CIEDs
had been implanted were enrolled in 6 Italian hospitals: the
107 patients enrolled in phase I (SC group) underwent in-
person follow-up examinations at 3, 6, 9, and 12 months; the
102 patients enrolled in phase II (RM group) underwent in-
person examinations on enrollment and after 12 months and
RM follow-up examinations at 3, 6, and 9 months by means
of a Merlin@home transmitter (St. Jude Medical) combined
with continuous monitoring according to predeﬁned techni-
cal and clinical alerts. Management strategies and data
collection were predeﬁned.
The study protocol was approved by the local ethics
committees responsible for each site. The investigation
conformed to the principles outlined in the Declaration of
Helsinki. All patients gave written informed consent, and
data were treated conﬁdentially.Study design
The objective of the study was to quantify the costs and
beneﬁts of RM vs SC from the perspectives of both the HCS
and the patient. Speciﬁcally, with regard to the HCS
perspective, we assessed health care services used (hospital-
izations, visits, and examinations). Concerning the patient
perspective, we assessed out-of-pocket expenses (eg, travel),
informal care (time spent by the caregiver), and the time
spent by the patient for follow-up. The use of health care
resources was deﬁned on the basis of hospital clinical
folders. Regarding the patient perspective, all data were
collected through case report forms administered to patients
during in-person visits.The beneﬁt outcomes were assessed by means of the EQ-
5D questionnaire (EuroQol ﬁve dimensions questionnaire).Cost analysis: HCS perspective
For both groups, the following costs were included for the
HCS perspective: all costs related to urgent and nonurgent
in-ofﬁce visits, scheduled and unscheduled remote follow-up
examinations, emergency service accesses, hospitalizations,
and diagnostic tests.
The costs associated with hospitalizations were calculated
in euros by using the diagnosis-related group tariffs (version
24). The diagnosis-related group economic values were
calculated using the Italian national reimbursement tariffs.15
The costs of in-ofﬁce follow-up visits and diagnostic tests
were estimated by using the national tariffs applied for these
services. In the Italian HCS, the cost of access to emergency
services is not available; this was therefore calculated by
considering the available regional reimbursement rates.16
In the Italian HCS, there is no established reimbursement for
RM; hence, the costs associated with scheduled and unsched-
uled RM sessions were considered to be zero in our analysis.
The time spent reviewing RM transmissions was measured
in order to have a raw estimate of the costs for the provider.Cost analysis: Patient perspective
In order to evaluate the socioeconomic impact of RM on
patients and caregivers, the following data points were
collected at each inhospital visit: (1) all costs incurred
in order to reach the hospital; (2) productivity loss, assessed
in terms of the number of working hours lost; (3) impact
on daily activity (number of hours); (4) cost of assistance,
assessed through the “market value” approach: speciﬁcally,
the cost of a care worker was applied to the hours that the
caregiver spent attending to the patient.17Beneﬁts
For the patient perspective, the quality of life associated with
the 2 strategies was assessed. The annual cost and the quality-
adjusted life-years (QALYs) of RM vs SC were calculated in
order to compare the 2 groups. QALYs were based on utility
(patients’ preferences). The EuroQoL EQ-5D-3L questionnaire
was administered to each patient at baseline and at 12 months18
in order to calculate utility values (from 0 to 1). Only if all 5 of
the EQ-5D dimensions were completed was utility deﬁned.
Moreover, missing utility values at 12 months were imputed
by using regression models, in which the dependent variable
was the utility value at 12 months and the independent variable
was the baseline value. QALYs were calculated from the area
under the curve of the mean utility values at 12 months
in relation to the baseline value. It was assumed that utility
values changed in a linear fashion from baseline to 12 months.
Utility values were calculated only for those patients who
completed the questionnaires at baseline and at 12 months and
for surviving patients.
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Continuous data are summarized as mean ± SD. Categorical
data are summarized as count and percentage and were
compared using the χ2 test or Fisher exact test, when
appropriate. Cost data are typically highly skewed19 since
a few patients incur particularly high costs; hence, the
Wilcoxon rank-sum test was used to compare costs across
groups. As TARIFF was not a randomized study, a multi-
variable linear regression analysis was also performed to
account for differences in baseline characteristics. This
analysis evaluated the impact of group membership (SC vs
RM) on total health care cost (outcome), adjusting for
covariates that were signiﬁcantly different between the
groups at the .2 signiﬁcance level. However, as the arith-
metic mean is the most informative measurement for policy
decisions, differences between the 2 groups were assessed
using differences in sample means (point estimates) and
t distributions (conﬁdence intervals). As the data were
skewed, these conﬁdence intervals were compared with
those based on the resampling-based bootstrap method
(1000 resampled data sets). In all cases, since the conﬁdence
interval widths from the 2 methods were on average within
2% (range 0%–5.1%) of each other, conﬁdence intervals are
reported from those based on the t distribution. Poisson
regression was used to compare the mean hospital visits inTable 1 Baseline clinical and socio-economic characteristics
Standard care (SC)
Male 92 (85.98)
Age 68.89 ± 11.46
NYHA:
I 25 (23.36)
II 51 (47.66)
III 28 (26.17)
IV 3 (2.80)
EF% (Mean ± Std) 32.25 ± 10.57
Primary Prevention Secondary
Prevention
83 (77.57)
24 (22.43)
Cardiomyopathy:
- Ischemic 62 (57.92)
- Dilated 34 (31.78)
- Hypertrophic 2 (1.87)
Brugada (%) 2 (1.87)
Other (%) 2 (1.87)
None (%) 2 (1.87)
Implanted device:
SC-ICD 30 (28.04)
DC-ICD 25 (23.36)
CRT-D 52 (48.60)
Total Distance Traveled at
Enrollment (km) (Mean ± Std [n])
43.61 ± 49.31 [10
Total Journey Cost at Enrollment (€)
(Mean ± Std [n])
9.91 ± 10.37 [10
Total Loss of work or activity at Enrollment for
patient (Hours) (Mean ± Std [n])
2.98 ± 1.63 [92]
Total Loss of work or activity at Enrollment for
caregiver (Hours) (Mean ± Std [n])
3.08 ± 1.67 [80]
Patients retired from work 84 (78.50)
Values are mean  SD (min, max) or mean difference (95% conﬁdence interva
CRT-D ¼ cardiac resynchronization therapy with deﬁbrillator; DC ¼ dual-cha
NYHA ¼ New York Heart Association; SC ¼ single-chamber.the 2 groups. A P value less than .05 was considered
signiﬁcant. All statistical analyses were performed in
SAS 9.3 and R version 3.2.3, SAS Institute Inc.,Cary, NC,
USA.Results
Baseline characteristics
The baseline characteristics of patients are summarized in
Table 1. The SC group comprised 107 (51.81%) patients;
and the RM group, 102 (48.19%). The baseline clinical
characteristics of the population enrolled were homogene-
ous, without signiﬁcant differences between the 2 groups.
Similarly, there were no signiﬁcant differences between the 2
groups with regard to social and economic proﬁle (journey
costs, distances, working activities, loss of productivity, and
prevalence of retired patients). During the study, 14 (6.70%)
patients died (9 (8.82%) in the RM group and 5 (4.67%) in
the SC group; P ¼ .41); 8 (3.83%) were withdrawn
(5 (4.90%) RM and 3 (2.80%) SC; P ¼ .49), and 12
(5.74%) were lost to follow-up (2 (1.96%) RM and 10
9.35%) SC; P ¼ .037), as shown in Figure 1; 89 SC patients
and 86 RM patients completed the 12-month study period.
All results are reported for these patients.[pts: 107] Remote Monitoring (RM) [pts: 102] p value
86 (84.31) .73
69.69 ± 10.17 .83
.14
30 (29. 41)
33 (32.35)
38 (37.25)
1 (0.98)
31.82 ± 9.58 .91
82 (78.95) .62
20 (21.05)
.38
55 (53.92)
40 (39.21)
3 (2.94)
0 (0.0)
3 (2.94)
1 (0.98)
.10
16 (15.69)
28 (27.45)
58 (56.86)
7] 43.80 ± 41.98 [102] .52
3] 11.20 ± 11.66 [99] .11
3.02 ± 1.34 [93] .51
3.45 ± 1.79 [75] .17
75 (74.64) .52
l).
mber; EF ¼ ejection fraction; ICD ¼ implantable cardioverter-deﬁbrillator;
Figure 1 Study diagram showing the number of patients enrolled in each
group. During the study, 14 patients died, 8 were withdrawn, and 12 were
lost to follow-up. FU ¼ follow-up; M ¼ month.
53Ricci et al TARIFF: Economic Analysis of Remote MonitoringHCS perspective
The components of the health care resources consumed are
presented in Figure 2. patients with SC underwent more
hospitalizations for cardiovascular reasons than did patients
with RM (SC: 22 (24.72%) vs RM: 7 (8.14%); P ¼ .0032),
more emergency department visits (SC: 5 (5.62%) vs RM: 0
(0.00%); P ¼ .059), more outpatient diagnostic tests (SC: 59
(66.29%) vs RM: 40 (46.51%); P ¼ .0083), and more
outpatient visits (SC: 26 (29.21%) vs RM: 14 (16.28%); P¼
.0416). Regarding cardiovascular hospitalizations, there was
no statistically signiﬁcant difference in the length of hospital
stay neither between patients with RM and patients with SC
(6.6 ± 4.7 days [44 hospitalizations] vs 6.4 ± 4.8 days [14
hospitalizations]; P ¼ .8990) nor according to the type of
device implanted (cardiac resynchronization therapy with
deﬁbrillator 6.8 ± 4.8 days [30 hospitalizations] vs single-/
dual-chamber implantable cardioverter-deﬁbrillator 6.3 ±
4.7 days [28 hospitalizations]; P ¼ .7014).Figure 2 Health care resource consumption in the 2 groPatients enrolled in the SC group had per protocol more
scheduled inhospital device follow-up visits than those enrolled
in the RM group (mean hospital visits 3.76 ± 0.52 vs 1.00 ±
0.00; Po .001). Conversely, patients enrolled in the RM group
had more unscheduled inhospital device follow-up visits than
did those enrolled in the SC group (0.66 ± 1.01 vs 0.13 ± 0.40;
P o .001). The total number of inhospital device follow-up
visits (scheduled þ unscheduled) was reduced by 58.78% in
the RM group (RM: 143 vs SC: 347; Po .0001) (Figure 3).
Health care costs are reported in detail in Table 2. The overall
mean annual costs for each patient with SC were signiﬁcantly
higher than those for each patient with RM (SC: €1044.89 ±
€1990.47 vs RM: €482.87 ± €2488.10; P o .0001), with a
reduction of 53.87% being achieved in the RM group. The
difference remained statistically signiﬁcant (difference (SC −
RM): €1053.41; P ¼ .0149) in the multivariable regression
analysis, which adjusted for the following variables that were
signiﬁcantly different at the .2 signiﬁcance level between the 2
groups at baseline: New York Heart Association class, total
journey cost at enrollment, type of device, and total loss of work
or activity at enrollment for caregivers. The mean annual costs
for patients with RM were signiﬁcantly lower than those for
patients with SC with regard to all items that contributed to the
overall costs, that is, cardiovascular hospitalizations, emergency
department visits, outpatient clinical evaluation visits, outpatient
diagnostic tests, and in-ofﬁce device follow-up visits. The main
driver of cost reduction, however, was constituted by cardiovas-
cular hospitalizations (SC: €886.67± €1979.13 vs RM: €432.34
± €2487.86; P ¼ .0030).
Remote transmission review
In the RM group, 473 remote transmissions to the center were
made by the home transmitter. Of these, 234 (49.47%) were
scheduled follow-up transmissions and 239 (50.53%) were
transmissions triggered by alerts. The success rate of remote
transmission was 90.70%. The most common triggers were atrial
arrhythmias 61 (25.52%), ventricular arrhythmias 24 (10.04%),ups. RM ¼ remote monitoring; SC¼ standard care.
Figure 3 Total number of inhospital device follow-up visits (scheduledþ
unscheduled) in the 2 groups. Patients in the RM group had 58.78% fewer
visits. RM ¼ remote monitoring; SC¼ standard care.
Heart Rhythm, Vol 14, No 1, January 201754heart failure events 81 (33.89%), and ST changes 31 (12.97%).
Distribution of alerts triggering unscheduled data transmission by
the patient home transmitter is presented in detail in Figure 4. The
time spent reviewing scheduled remote follow-up data and alert-
triggered transmissions was, on average, 4.46 ± 3.35 and 5.89 ±
8.58 minutes, respectively. Considering all remote transmissions
(473), we calculated a mean annual time for transmission
revision of 47.92 hours per 100 patients.Patient perspective and quality of life
Detailed patient costs, including traveling, and loss of work
and of daily activities for patients and caregivers are sum-
marized in Table 3. The total annual costs per patient were, on
average, €169.49 ± €189.50 in the SC group vs €56.87 ±
€80.22 in the RM group (Po .0001), resulting in a reduction
of 66.44%. The average monetary value attributed to the hours
spent by the accompanying person, as calculated by means of
the “market value” approach, was €60.14 ± €33.37 in the SC
group vs €17.81 ± €11.65 in the RM group (Po .0001).Table 2 Health care costs: payer perspective
Variable SC RM
Cardiovascular
hospitalization costs (€)
886.67 ± 1979.13 (0, 12436) 432.34 ± 2
Device-related costs (€) 229.07 ± 1186.25 (0, 9384) 0.00 ± 0
Cardiovascular-related
costs (€)
657.61 ± 1470.90 (0, 7523) 432.34 ± 2
Emergency visit costs
(only emergency
department access) (€)
15.67 ± 66.25 (0, 310) 0.00 ± 0
Costs of outpatient clinical
evaluations (€)
5.22 ± 9.28 (0, 39) 2.10 ± 4
Costs of outpatient
diagnostic tests (€)
46.72 ± 46.54 (0, 178) 9.79 ± 2
Total costs for scheduled
in-ofﬁce follow-up
visits (€)
87.48 ± 12.15 (46, 93) 23.24 ± 0
Total costs for
unscheduled in-ofﬁce
follow-up visits (€)
3.13 ± 9.40 (0, 46) 15.40 ± 2
Total health care costs (€) 1044.89 ± 1990.47 (46, 12,542) 482.87 ± 2
Values are mean  SD (min, max) or mean difference (95% conﬁdence interva
RM ¼ remote monitoring; SC ¼ standard care.Utility values and QALYs over the 12-month study period
are reported in Table 4. There were no signiﬁcant differences in
QALYs between the SC group and the RM group in any
scenario.Discussion
The main result of the TARIFF study is that, from the HCS
perspective, an RM strategy for managing patients with
CIED reduced the overall annual health care costs by 53.87%
in comparison with a standard follow-up strategy. This cost
reduction was due to a marked reduction in the consumption
of health care resources, including hospitalizations for
cardiovascular reasons, emergency department visits, out-
patient diagnostic tests, outpatient clinical evaluation visits,
and device follow-up visits. Overall inhospital device
follow-up visits were reduced by more than 50% in the
RM group, in which monitoring was continuous. This means
that in spite of the high number of remote alerts received,
most were remotely managed without inhospital visits. Our
ﬁndings are consistent with those of previous studies in the
ﬁeld.5,11,13 Unlike the ECOST (The Effectiveness and Cost
of ICD followup Schedule with Telecardiology) trial,20 in
which hospitalization costs per patient-year were not sig-
niﬁcantly reduced in the RM group, the TARIFF study found
that the main driver of cost reduction was the reduction in
cardiovascular hospitalizations, which was responsible for
81% of saving. Our ﬁndings differ from the review by Burri
et al21 from a UK National Health Service perspective, in
which, over 10 years, RM was predicted to be cost-neutral at
about £11,500 per patient in either treatment arm. However,
the model applied by Burri et al was conservative, in that it
did not assume a reduction in cardiovascular events in
patients with RM and did not include the patient perspectiveDifference (SC − RM)
P (Wilcoxon
rank-sum test)
487.86 (0, 20,486) 454.34 (−218.17 to 1126.84) .0030
.00 (0, 0) 229.07 (−20.82 to 478.95) .0496
487.86 (0, 20,486) 225.27 (−388.31 to 838.85) .0136
.00 (0, 0) 15.67 (1.71 to 29.62) .0278
.79 (0, 13) 3.12 (0.92 to 5.32) .0259
0.30 (0, 141) 36.93 (26.24 to 47.61) o.0001
.00 (23, 23) 64.24 (61.68 to 66.80) o.0001
3.54 (0, 116) −12.27 (−17.67 to −6.87) o.0001
488.10 (23, 20,534) 562.02 (−111.98 to 1236.01) o.0001
l).
Figure 4 Distribution of alerts triggering unscheduled data transmission by the patient home transmitter. HF ¼ heart failure; PMT ¼ pacemaker-mediated
tachycardia; ST ¼ ST segment elevation/depression on internal electrogram.
55Ricci et al TARIFF: Economic Analysis of Remote Monitoringin the analysis. Moreover, cost savings due to better timing
of elective device replacement and the fact that fewer follow-
up visits are needed in patients nearing device replacement
were not considered. In the Clinical Evaluation of Remote
Notiﬁcation to Reduce Time to Clinical Decision trial,7
patients randomized to the remote arm had signiﬁcantly shorter
hospitalization stays than those randomized to the in-ofﬁce
arm, with an estimated $1659 saving per hospitalization. In the
COMPAS (COMPArative followup Schedule with Home
Monitoring) trial,6 hospitalizations for atrial arrhythmias and
strokes were fewer in the active arm than in the control group.
In the IN-TIME (INﬂuence of Home MoniToring on mortality
and morbidity in heart failure patients with an IMpaired lEft
ventricular function) trial,22 there were no differences in hospital-
izations between RM and control groups, but mortality at 1 year
was signiﬁcantly reduced in the RM arm by 61%.
Even from the patient perspective, RM had a favorable
impact, yielding a 66.44% reduction in patient costs. This
ﬁnding is particularly meaningful from the social perspective
and may implement patient adherence to follow-up scheduleTable 3 Cost incurred by patients
Variable SC ( n¼ 89)
Total distance traveled (km) 165.54 ± 209.13
Total journey cost (€) 36.81 ± 40.83
Total loss of work or activity for patients (h) 10.43 ± 5.38
Total loss of work or activity for caregivers (h) 11.35 ± 6.30 (69)
Monetary value of caregiver loss of work or
activity (€)
60.14 ± 33.37 (69)
Mean annual cost for each patient (€) 169.49 ± 189.50
Values are mean  SD (min, max) or mean difference (95% conﬁdence interva
RM ¼ remote monitoring; SC ¼ standard care.and therapy compliance. Interestingly, the EVOLVO
(Evolution of Management Strategies of Heart Failure Patients
With Implantable Deﬁbrillators) study23 did not demonstrate
any cost saving in the RM group from the HCS perspective,
while it did from the patient perspective. In line with the
EVOLVO study, utility values and QALYs over the 12-month
study period did not show any difference between the 2 groups.
The TARIFF study results represent a situation in which,
through the use of RM instead of SC, a similar level of
outcome (QALYs) is obtained at a lower cost. This case does
not require calculating the incremental cost-effectiveness ratio
(needed when the new alternative is both more expensive and
more effective than the old one). RM is consequently to be
regarded as a “cost-saving” strategy in comparison with SC.
In the TARIFF study, the costs associated with scheduled
and unscheduled RM sessions were artiﬁcially considered to
be zero since in Italy, as in other countries, there is no
reimbursement for RM. This makes RM unsustainable for
the provider. The reimbursement tariff for RM should cover
the time spent reviewing alerts and RM transmissions, theRM (n ¼ 86) Difference (SC − RM)
P (Wilcoxon
rank-sum test)
45.20 ± 41.87 120.34 (75.43–165.25) o.0001
10.95 ± 10.75 25.86 (16.97–34.74) o.0001
2.67 ± 1.97 7.76 (6.55–8.96) o.0001
3.36 ± 2.20 (57) 7.99 (6.37–9.60) o.0001
17.81 ± 11.65 (57) 42.34 (33.78–50.89) o.0001
56.87 ± 80.22 112.62 (69.32–155.92) o.0001
l).
Table 4 Utility values and quality-adjusted life-years over the 12-mo study period
Variable SC (n ¼ 87) RM (n ¼ 79) Difference (phase II − phase I) P (t test)
Utility at baseline 0.86 ± 0.18 0.87 ± 0.13 0.01 (−0.04 to 0.06) .80
Utility at 12 mo 0.85 ± 0.18 0.87 ± 0.16 0.02 (−0.03 to 0.08) .38
Quality-adjusted life-years 0.85 ± 0.17 0.87 ± 0.13 0.02 (−0.03 to 0.06) .53
Values are mean ± SD or mean difference (95% conﬁdence interval).
RM ¼ remote monitoring; SC ¼ standard care.
Heart Rhythm, Vol 14, No 1, January 201756time needed for administrative duties, patient phone calls and
general management activity, and the cost of the transmitter.
Even if the HC authority establishes a reimbursement for
RM, it will still be cost saving for the HCS. For example, if
the same tariff as in-ofﬁce device follow-up was assigned to
the 473 annual transmissions recorded in the RM group
during the TARIFF study, it would result in a total annual
cost of around €11,000. The average annual cost per patient
would be €128. If this value was added to the annual cost of
RM, the RM strategy would still prove to be cost saving in
comparison with SC.
This ﬁnding is in agreement with those of the European
Health Economic Trial on Home Monitoring in ICD Patients
trial,24 in which, on comparing RM with SC strategies, there
was no difference in the net ﬁnancial impact on providers;
however, there was heterogeneity among countries, with RM
generating less proﬁt for providers in the absence of speciﬁc
reimbursements and maintained or increased proﬁt in cases
in which such reimbursement existed. Anyway, from the
HCS perspective even in countries with reimbursement, RM
was never more costly than SC. Indeed, according to a recent
European survey,25 the lack of reimbursement is generally
perceived as a major barrier to the implementation of RM in
standard practice.
The RM technology used in this study showed good
performance; the success rate of remote transmission was
90.7%, similar to that of other proprietary systems. The time
spent reviewing transmissions was quite short (4.5 minutes
for remote follow-up and 5.9 minutes for alert-triggered
transmissions). We may speculate that the prevalence
of actionable events was greater in alert-triggered trans-
missions than in scheduled transmissions and that actionable
events were the main responsible for the difference in
time consumption between alert-triggered and scheduled
transmissions.
Similar results have been reported for other systems that
use similar technology. As also in the TRUST (The Lumos-T
Safely Reduces Routine Ofﬁce Device Follow-Up) study,9
patient adherence to the follow-up program was superior in
the RM group.Clinical implications
RM reduced hospitalizations for cardiovascular reasons from
24.7% to 8.1%. This may impact on patient outcome. Taking
into account that atrial and ventricular arrhythmias, heart
failure events, and ST changes were the most common
triggers for alerts, we may speculate that early reaction to
potentially catastrophic events may have prevented seriouscomplications. Previous studies and registries have demon-
strated that RM can prevent stroke6,26 and the progression of
heart failure22 and may reduce mortality.1,22
Study limitations
The main limitation of the TARIFF study is that consecutive
patients were enrolled in the 2 arms and that it was not a
randomized study. Nevertheless, the populations in the 2
arms were homogeneous not only in terms of clinical proﬁle
but also from the socioeconomic perspective. Patient follow-
up was per protocol 12 months, and we cannot speculate on
the comparison for longer follow-up.
The TARIFF study provides a picture of “real-life”
practice in Italy; the results could differ in different HCSs
and in different economic and social settings.
Alert setting and clinical reaction to cardiovascular events
were left to the investigator’s discretion. As manpower
analysis focused on patient’s RM, the time devoted to
enrollment and phone calls, or unanswered calls and
unsuccessful attempts, was not calculated. Finally, the time
spent contacting the physician responsible, when necessary,
was not included.
We evaluated only 1 automatic wireless RM technology.
Thus, our results cannot be transferred to other proprietary
technologies with their varying transmission frequencies and
methods of alert notiﬁcation.
Conclusion
The results of the TARIFF study show that the RM of
patients with CIEDs appears to be a cost-saving solution for
the HCS in comparison with the conventional method of in-
clinic visits. Furthermore, RM is cost saving for patients and
caregivers. Lack of reimbursement is a critical issue from the
provider perspective. Introducing appropriate reimbursement
would make RM attractive even for the provider, while it
would still be cost saving for the HCS.
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